Sunitinib News and Research

RSS
Sunitinib malate is approved by the Food and Drug Administration (FDA) to treat a type of stomach cancer called gastrointestinal stromal tumor (GIST). It is used in patients whose condition has become worse while taking another drug called imatinib mesylate or who are not able to take imatinib mesylate.
Treatment with sunitinib slows tumor growth and spread of liver cancer

Treatment with sunitinib slows tumor growth and spread of liver cancer

Biomarkers allow doctors to match therapy to patient

Biomarkers allow doctors to match therapy to patient

Benefits of some cancer drugs exaggerated because trials were stopped early

Benefits of some cancer drugs exaggerated because trials were stopped early

Sunitinib may be associated with cardiac toxicity

Sunitinib may be associated with cardiac toxicity

Re-engineered Gleevec reduces heart risks

Re-engineered Gleevec reduces heart risks

Blood markers can help choose best dose for antiangiogenic drugs

Blood markers can help choose best dose for antiangiogenic drugs

Axitinib shows promise for patients with advanced kidney cancer

Axitinib shows promise for patients with advanced kidney cancer

Results of phase II studies of pazopanib

Results of phase II studies of pazopanib

FDA approves Torisel (temsirolimus) for advanced kidney cancer

FDA approves Torisel (temsirolimus) for advanced kidney cancer

Sunitinib halts progress of metastatic kidney cancer

Sunitinib halts progress of metastatic kidney cancer

Sunitinib shows promise in treating metastatic renal cell cancer

Sunitinib shows promise in treating metastatic renal cell cancer

Sunitinib therapy shows promise in children with metastatic gastrointenstinal stromal tumor

Sunitinib therapy shows promise in children with metastatic gastrointenstinal stromal tumor

Sunitinib malate shows promise against advanced form of lung cancer

Sunitinib malate shows promise against advanced form of lung cancer

Sunitinib malate drug shows significant benefits over standard treatment for advanced kidney cancer

Sunitinib malate drug shows significant benefits over standard treatment for advanced kidney cancer

Therapy for metastatic renal cell carcinoma remains inadequate

Therapy for metastatic renal cell carcinoma remains inadequate